and according to Merck has the potential to become a $3 billion product at peak for PAH, thanks to its to become the first drug for PAH that addresses the underlying disease process rather than ...
Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback